Novo Nordisk A/S, a global healthcare leader in diabetes care, reported a significant increase in sales and operating profit for the first half of 2024. Sales rose by 24% in Danish kroner and 25% at constant exchange rates (CER) to DKK 133.4 billion, while operating profit grew by 18% in Danish kroner and 19% at CER to DKK 57.8 billion. The company's performance was particularly strong in North America, with a 36% increase in sales. Diabetes and Obesity care sales surged by 26% in Danish kroner, driven by GLP-1 diabetes sales growth and Obesity care growing by 37% in Danish kroner. However, rare disease sales saw a decrease. Novo Nordisk also completed the phase 3 FRONTIER 2 trial with Mim8 for haemophilia A and received a positive CHMP opinion for Wegovy in the EU. The company updated its 2024 outlook, expecting sales growth of 22-28% at CER and operating profit growth of 20-28% at CER. The financial report was released on August 7, 2024, alongside an earnings call for investors.

Novo Nordisk A/S, a global healthcare leader in diabetes care, reported a significant increase in sales and operating profit for the first half of 2024. Sales rose by 24% in Danish kroner and 25% at constant exchange rates (CER) to DKK 133.4 billion, while operating profit grew by 18% in Danish kroner and 19% at CER to DKK 57.8 billion. The company's performance was particularly strong in North America, with a 36% increase in sales. Diabetes and Obesity care sales surged by 26% in Danish kroner, driven by GLP-1 diabetes sales growth and Obesity care growing by 37% in Danish kroner. However, rare disease sales saw a decrease. Novo Nordisk also completed the phase 3 FRONTIER 2 trial with Mim8 for haemophilia A and received a positive CHMP opinion for Wegovy in the EU. The company updated its 2024 outlook, expecting sales growth of 22-28% at CER and operating profit growth of 20-28% at CER. The financial report was released on August 7, 2024, alongside an earnings call for investors.